Literature DB >> 730111

Immunoreactive granulocyte elastase in human serum.

K Ohlsson, A S Olsson.   

Abstract

A specific radioimmunoassay has been developed for determination of human granulocyte elastase in blood. THE granulocyte elastase employed as radioiodinated tracer in the assay was inactivated with diisopropylfluorophosphate in order to prevent binding of the tracer to the serum inhibitors alpha2-microglobulin and alpha1-anti-trypsin, while still retaining its immunoreactivity. The labelled tracer showed, however, a pronounced tendency to nonspecific binding to serum proteins such as albumin and alpha2-macroglobulin and also to the Sephadex particles. The binding of the labelled tracer to alpha2-macroglobulin caused a false increase in the immunoreactive granulocyte elastase in serum. But the binding of the labelled tracer and its consequences could be circumvented by increasing the NaCl concentration of the reaction mixtures and/or gel filtration buffers. Freshly drawn normal human serum contains about 135 microgram granulocyte elastase/l measured as diisopropylfluorophosphate-inactivated granulocyte elastase. The results of experiments in which serum was fractionated by Sephadex G-100 gel filtration suggest that essentially all of the immunoreactive material in normal human serum is granulocyte elastase bound by alpha1-antitrypsin. This finding implies that granulocyte elastase is released from the cells in an active form and then rapidly bound by the inhibitors.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 730111     DOI: 10.1515/bchm2.1978.359.2.1531

Source DB:  PubMed          Journal:  Hoppe Seylers Z Physiol Chem        ISSN: 0018-4888


  10 in total

1.  Diagnosis and therapy of bacterial endophthalmitis, and serum levels of inflammation markers.

Authors:  V Huber-Spitzy; E Arocker-Mettinger; K Herkner; M Schiffbänker; L Georgiew; F J Steinkogler; G Grabner
Journal:  Infection       Date:  1992 May-Jun       Impact factor: 3.553

2.  Inflammatory mediators of systemic inflammation in neonatal sepsis.

Authors:  V Sugitharini; A Prema; E Berla Thangam
Journal:  Inflamm Res       Date:  2013-09-08       Impact factor: 4.575

3.  Hemorrhagic pancreatitis.

Authors:  W H Marks; K Ohlsson
Journal:  Ann Surg       Date:  1980-12       Impact factor: 12.969

4.  Leukocyte elastase release during blood coagulation. A potential mechanism for activation of the alternative fibrinolytic pathway.

Authors:  E F Plow
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

5.  Glutathione in bronchoalveolar lavage fluid from smokers is related to humoral markers of inflammatory cell activity.

Authors:  M Linden; L Håkansson; K Ohlsson; K Sjödin; H Tegner; A Tunek; P Venge
Journal:  Inflammation       Date:  1989-12       Impact factor: 4.092

6.  Serum studies of leucocyte elastase in acute and chronic lung diseases.

Authors:  R A Stockley; K Ohlsson
Journal:  Thorax       Date:  1982-02       Impact factor: 9.139

7.  Serum elastase 1 in chronic pancreatic disease.

Authors:  G Del Favero; C Fabris; M Plebani; A Panucci; A Piccoli; L Perobelli; A Burlina; R Naccarato
Journal:  Klin Wochenschr       Date:  1985-07-01

8.  Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase.

Authors:  R C Thompson; K Ohlsson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

9.  Human cystatin C. role of the N-terminal segment in the inhibition of human cysteine proteinases and in its inactivation by leucocyte elastase.

Authors:  M Abrahamson; R W Mason; H Hansson; D J Buttle; A Grubb; K Ohlsson
Journal:  Biochem J       Date:  1991-02-01       Impact factor: 3.857

10.  Expression of Serum Cytokines Profile in Neonatal Sepsis.

Authors:  Suipeng Chen; Mengjiao Kuang; Ying Qu; Shirui Huang; Binbin Gong; Suzhen Lin; Huiyan Wang; Guiye Wang; Hongqun Tao; Jian Yu; Zuqin Yang; Minghua Jiang; Qipeng Xie
Journal:  Infect Drug Resist       Date:  2022-06-30       Impact factor: 4.177

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.